Speaker Profile
M.D., CMO, Natera
Biography
Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefit and outcomes in solid tumors and in developing novel therapeutics to improve survival, with a particular focus in breast cancer. She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium. Dr. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Adrian Lee, University of Pittsburgh
PMWC Award Ceremony Honorees
• Dennis J. Slamon, UCLA
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, UPenn
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Pedram Razavi, MSK
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
From Validation to Payment: Coverage Pathways That Work
• Mark Stewart, Friends of Cancer Research
From Validation to Payment: Coverage Pathways That Work
• Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society (ACS)
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
